IP Library Granted Patent US 9,925,267
Granted Patent B2
US 9,925,267 · App. 15/166,801 · Granted Mar 27, 2018

Polylactide compositions and uses thereof

Inventors: Michael Moller (Geneva, CH); Thomas Trimaille (Marseilles, FR); Robert Gurny (Geneva, CH)
Assignee: University of Geneva
A61K47/34A61K9/0019A61K9/0024A61K9/1075A61K31/65C08G63/08C08G63/823
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,925,267
App. No.
15/166,801
Granted
Mar 27, 2018
Kind
B2
Abstract

The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Claims (27)

1. A pharmaceutical composition comprising a polylactide and a drug, wherein the polylactide has the structure:

wherein:

R 1 , R 2 , R 3 , and R 4 are each independently chosen from the group consisting of unsubstituted C 1-20 alkyl and hydrogen;

n is 2 to 100;

X is hydrogen;

at least one of R 1 , R 2 , R 3 , and R 4 is C 4-20 unsubstituted alkyl;

Y is —OH;

wherein the pharmaceutical composition is formulated for injection; and

wherein the polylactide has a T g value of less than 15° C.

2. The composition of claim 1 , wherein the pharmaceutical composition is formulated for parenteral, intravenous, intradermal, transdermal, intrathecal, intraarterial, intraperitoneal, intramuscular, infusion, or subcutaneous administration.

3. The composition of claim 2 , wherein the pharmaceutical composition is formulated for parenteral administration.

4. The composition of claim 2 , wherein the pharmaceutical composition is formulated for intramuscular administration.

5. The composition of claim 2 , wherein the pharmaceutical composition is formulated for subcutaneous administration.

6. The composition of claim 1 , wherein n is 2 to 75.

7. The composition of claim 6 , wherein n is 2 to 50.

8. The composition of claim 7 , wherein n is 2 to 25.

9. The composition of claim 1 , wherein R 1 and R 3 are hydrogen; wherein R 2 is —(CH 2 ) m —CH 3 , and wherein m is from 3 to 12.

10. The composition of claim 9 , wherein m=4-6.

11. The composition of claim 9 , wherein m=5.

12. The composition of claim 6 , wherein R 1 and R 3 are hydrogen; wherein R 4 is —(CH 2 ) m —CH 3 , and wherein m is from 3 to 12.

13. The composition of claim 12 , wherein m=4-6.

14. The composition of claim 13 , wherein m=5.

15. The composition of claim 8 , wherein R 1 and R 3 are hydrogen; wherein R 2 and R 4 are —(CH 2 ) m —CH 3 , and wherein m is from 3 to 12.

16. The composition of claim 1 , wherein the pharmaceutical composition is formulated for injection.

17. The composition of claim 16 , wherein R 1 and R 3 are hydrogen; and wherein R 2 and R 4 are —(CH 2 ) m —CH 3 or —CH 3 , wherein m=3-12.

18. The composition of claim 17 , wherein m=4-6.

19. The composition of claim 18 , wherein m=5.

Continuity (6)
Division 14258357 · Apr 22, 2014
Division 13778038 · Feb 26, 2013
Continuation 11912102
Provisional Application 60750141 · Dec 14, 2005
Provisional Application 60674103 · Apr 22, 2005
Related Publication 20160367680A1 · Dec 22, 2016